COMMISSIONERS: Lina M. Khan, Chair
Rebecca Kelly Slaughter
Alvaro M. Bedoya

In the Matter of

1HEALTH.IO INC., a corporation, also d/b/a VITAGENE, INC.

COMPLAINT

The Federal Trade Commission (“FTC”), having reason to believe that 1Health.io Inc., also doing business as Vitagene, Inc. and Vitagene, a corporation (“Respondent”), has violated the provisions of the Federal Trade Commission Act, and it appearing to the Commission that this proceeding is in the public interest, alleges:

1. Respondent 1Health.io Inc., also doing business as Vitagene, Inc. and Vitagene (“1Health.io” or “Vitagene”), is a Delaware corporation with its principal office or place of business at 201 Spear Street, Suite 1100, San Francisco, California 94105. Respondent changed its name from Vitagene, Inc. to 1Health.io Inc. in October 2020.

2. Respondent has developed, advertised, offered for sale, sold, and distributed products to consumers, including DNA test kits, through its websites, https://1health.io and https://vitagene.com (“Vitagene Website”), and other outlets, such as www.amazon.com.

3. The acts and practices of Respondent alleged in this complaint have been in or affecting commerce, as “commerce” is defined in Section 4 of the Federal Trade Commission Act.

RESPONDENT’S DNA HEALTH TEST KITS AND RELATED PRODUCTS

4. Since 2015, Respondent has sold Vitagene-branded “DNA Health Test Kits” to consumers. In each DNA Health Test Kit, Respondent instructs the consumer to provide a saliva sample by mail. Respondent contracts with a testing lab to analyze the sample and map a portion of the consumer’s genetic code.

5. Respondent combines the lab’s DNA analysis with the consumer’s answers to an online “health questionnaire” that probes the individual’s health history, lifestyle, and family health
history. Using this information, Respondent generates reports about the consumer’s health and wellness (“Health Reports”) and ancestry.

6. Respondent also sells to consumers Health Reports that Respondent creates by using consumers’ answers to an online “lifestyle questionnaire” and raw DNA data that consumers send to Respondent after the consumers have obtained DNA tests from certain companies other than Respondent.

7. In addition to DNA Health Test Kits, Health Reports, and ancestry reports, Respondent’s products include nutritional, fitness, and beauty plans and nutritional supplements customized to each consumer’s unique DNA.

8. The retail cost for a single DNA Health Test Kit, Health Report, and ancestry report ranges from $29 to $259, with high-end kits including add-ons, such as subscriptions to personalized vitamin packs and nutritional coaching.

9. The Health Reports that Respondent creates contain numerous facts about the consumer’s genetics and health. For example, one type of Health Report first lists the consumer’s name, date of birth, and referring doctor or dietician, and then identifies salient genotype data, pertinent questionnaire answers, and, based on the genotype data and questionnaire answers, the level of risk for having or developing certain health conditions, such as high LDL cholesterol, high triglycerides, obesity, or blood clots.

**RESPONDENT’S DECEPTIVE PRIVACY AND SECURITY PROMISES**

10. Since at least 2018, Respondent has made numerous, prominent claims about the privacy and security of the sensitive health and genetic information it collects and maintains. For example, the Vitagene Website’s home page, [https://vitagene.com](https://vitagene.com), devotes a section to “DNA Testing Privacy” that, as shown below, prominently features an image of a large padlock over a strand of DNA and asserts: “Your DNA and health details are personal and private. We make your privacy our priority.”
11. As shown above, the Vitagene Website home page includes a button that consumers can click to “Learn more” about Respondent’s “DNA Testing Privacy.” That button provides a link to a webpage on the Vitagene Website that Respondent devotes to describing Respondent’s privacy practices, https://vitagene.com/privacy/. Like the Vitagene Website home page, as shown below, the website’s privacy webpage prominently features images of padlocks, with the large-type, bold-faced heading: “The most personal information must also be the most private.” (Emphasis in original). Under that heading, Respondent asserts: “[W]e design innovative ways to protect your data and build powerful safeguards into our platform to ensure the safety of your personal information. As your lifelong partner on your health journey, your privacy is our top priority.” (Emphasis in original).

12. On the Vitagene Website privacy webpage, as shown below, under the bold-faced heading, “Experience personalization without sacrificing privacy,” Respondent features an image of a padlock with the sub-heading “Rock-solid Security.” (Emphasis omitted). Accompanying this image and sub-heading is the statement: “We use the latest technology and exceed industry-standard security practices to protect your privacy.”

13. Also on the Vitagene Website privacy webpage, Respondent gives its consumers additional assurances of its careful privacy and security practices. For example, as shown below, Respondent asserts, in bold-faced type: “Vitagene collects, processes, and stores your personal information in a responsible, transparent and secure environment that fosters our
customers’ trust and confidence.” At the bottom of this webpage, Respondent further represents in bold typeface: “Your health information is yours, and yours only. Your trust means a great deal to us, and drives our continued commitment to protecting your privacy.”

14. Respondent reiterates these claims about its commitment to privacy and security throughout the Vitagene Website. For example, as shown below, on a webpage titled “How It Works,” https://vitagene.com/how-it-works/, Respondent represents: “We believe that genetic information deserves the highest level of security. Therefore, your privacy is a top priority at Vitagene.”

Take the guesswork out of achieving your goals
We believe that genetic information deserves the highest level of security. Therefore, your privacy is a top priority at Vitagene. Rest assured, your enrollment information, health goals, medical history, and genetic information will be protected by industry standard security practices.
RESPONDENT’S DECEPTIVE PROMISES TO SEPARATE DNA FROM OTHER IDENTIFYING INFORMATION

15. Since at least 2018, Respondent has described a specific manner in which it protects the privacy and security of consumers’ information: separating DNA from any other identifying information. Specifically, since at least 2018, on the Vitagene Website “How It Works” webpage and as shown below, Respondent has provided a list of “[t]hree of the ways we protect your privacy,” which includes separation of DNA results from identifying information: “Your results and DNA sample are stored without your name or any other common identifying information.”

Three of the ways we protect your privacy:
1. Your results and DNA sample are stored without your name or any other common identifying information.

16. Respondent prominently repeats this claim about separation of DNA and other identifying information elsewhere on the Vitagene Website. On a webpage devoted to answering “Frequently Asked Questions,” https://vitagene.com/frequently-asked-questions/, as shown below, Respondent answers the questions, “Is my data protected?” and “How is my privacy protected?,” by asserting (in part): “Your results and DNA [“sample” or “files”] are stored without any identifying information….”

RESPONDENT’S DECEPTIVE PROMISE TO DELETE ALL DATA UPON CONSUMER REQUEST

17. Since at least 2018, Respondent has promised that consumers can readily delete all of their information. On the Vitagene Website privacy webpage, as shown below, under the sub-heading “You’re in control of your data,” Respondent has represented: “You can delete your data at any time. This will remove your information from all of our servers.”
RESPONDENT’S DECEPTIVE PROMISE TO DESTROY DNA SALIVA SAMPLES

18. Since at least 2018, Respondent has promised on multiple webpages that it destroys the physical DNA samples it collects from consumers after the samples have been analyzed. Specifically, on the Vitagene Website “How It Works” webpage, and as shown below, Respondent has represented: “Vitagene destroys your physical DNA saliva sample after it has been analyzed.” As also shown below, Respondent repeats this claim on the Vitagene Website “Frequently Asked Questions” webpage, in response to the question: “Is my data protected?” (“your physical sample is destroyed after it is processed”).

Three of the ways we protect your privacy:
1. Your results and DNA sample are stored without your name or any other common identifying information.
2. Vitagene destroys your physical DNA saliva sample after it has been analyzed.
3. We don’t share your information with any third party without your explicit consent.

Is my data protected?

Vitagene uses industry standard security practices to store and protect your DNA sample, results, and any additional information you provide. Your results and DNA sample are stored without any identifying information and your physical sample is destroyed after it is processed. Vitagene does not share your information with any third party without your explicit consent.

19. Beginning in approximately December 2016, Respondent lacked measures to ensure that consumers’ saliva samples were destroyed shortly after they had been analyzed. In particular, Respondent did not have a contract provision with its genotyping laboratory partner requiring such destruction.
20. From at least 2017 until April 2020, Respondent’s privacy policy defined “personal information” to include “Enrollment Information, Family History, Lab work, Health Goals, Medical History, Genetic Data, and Enrollment Form.” The privacy policy also stated: “A large portion of the Personal Information we collect, use, share, and store is sensitive in nature, including any and all medical information for example Genetic Data & Other Personal Information.”

21. Consistent with Respondent’s numerous prominent claims about maintaining privacy and security for the sensitive health and genetic information Respondent collects from consumers, from at least 2017 until April 2020, Respondent’s privacy policy stated that Respondent would share consumers’ personal information with third parties only in limited circumstances for narrow purposes. Specifically, the privacy policy stated that Respondent would share consumers’ personal information with their physicians or other medical professionals under consumers’ direction; with Respondent’s business partners or service providers, such as credit card processors or contracted genotyping laboratories, “only as necessary to” help Respondent provide, understand, or improve its services; as required by law; with any third party with a consumer’s prior consent; or via transfer of Respondent’s business to another entity. During part of that time period, Respondent’s privacy policy also stated that Respondent would share consumers’ personal information with business partners, affiliates, sponsors, or other third parties in an aggregate, non-personally identifiable form.

22. From at least 2017 to April 2020, Respondent’s privacy policy also stated: “We reserve the right to update, change, modify or otherwise alter this Privacy Policy at any time. If any material changes are made to this Privacy Policy, Vitagene will notify you by posting the revised Privacy Policy on the Services or notifying you through the Services. ANY ACCESS OR USE OF THE SERVICES BY YOU AFTER THE CHANGES GO INTO EFFECT SHALL CONSTITUTE AND BE DEEMED YOUR AGREEMENT TO THIS PRIVACY POLICY.”

23. In April and December 2020, Respondent published revised privacy policies (collectively, “Respondent’s 2020 privacy policies”) that apply to all of Respondent’s customers, including those who purchased products and services from Respondent solely before April 2020. Compared to Respondent’s previous privacy policy, Respondent’s 2020 privacy policies significantly expand the types of third parties with whom, and the purposes for which, Respondent may share consumers’ personal information. For example, Respondent’s 2020 privacy policies state that Respondent shares personal information with third parties such as pharmacies, supermarket chains, nutrition and supplement manufacturers, and other providers and retailers so they can promote and offer their products and services to Respondent’s customers; with third parties for their own services and marketing purposes unless a customer opts out of such sharing; and with partners, third parties, or affiliates, including for those third parties’ own purposes. Respondent’s December 2020 version of its privacy policy currently remains in effect.
24. When Respondent posted the 2020 privacy policies, Respondent did not take any additional steps to notify consumers who had provided sensitive personal information to Respondent prior to the 2020 privacy policy changes or to obtain consumers’ consent for the material changes to its policies with respect to the sharing of such information, including sharing that Respondent’s previously posted privacy policy had stated would take place only with the consumer’s consent.

25. Although Respondent has not yet implemented the broader information sharing practices stated in its 2020 privacy policies, it could do so at any time without further notice to consumers.

RESPONDENT’S PUBLIC EXPOSURE OF CONSUMERS’ HEALTH AND GENETIC INFORMATION

26. As part of its information technology infrastructure, Respondent uses Amazon Web Services’ (“AWS’s”) Simple Storage Service (the “Amazon S3 Datastore”). The Amazon S3 Datastore is a scalable cloud storage service that entities use to store and retrieve data in virtual containers, called “Buckets.”

27. Respondent stores a variety of files containing sensitive health and genetic information in Amazon S3 Datastore Buckets. These files include, among other things, consumers’ Health Reports; genotype data called single-nucleotide polymorphisms (“SNPs”), which are the most common type of genetic variation among people; and other raw genotype data.

28. Despite the fact that Respondent stores consumers’ sensitive personal information in the Amazon S3 Datastore, Respondent did not uniformly apply basic safeguards to the data in each of its Amazon S3 Datastore Buckets. In or about 2016, Respondent created a publicly accessible Bucket in which Respondent stored Health Reports for at least 2,383 consumers and a publicly accessible Bucket in which Respondent stored raw genetic data (sometimes accompanied by first name) for at least 227 consumers (“Health and Genetic Buckets”). Respondent did not use any access controls to restrict access to this sensitive data, encrypt it, log or monitor access to it, or inventory it to help ensure ongoing security. As a result of Respondent’s disregard for the basic security of the Health and Genetic Buckets, Respondent publicly exposed online the health and genetic information of more than 2,600 consumers.

29. Between July 2017 and June 2019, Respondent received at least three warnings that it was storing consumers’ unencrypted health, genetic, and other personal information in publicly accessible Buckets.

30. Respondent received its first warning in July 2017. At that time, AWS sent Respondent an email message, with the subject line “Securing Amazon S3 Buckets,” “to remind [Respondent] that one or more of [its] Amazon S3 bucket access control lists (ACLs) [was] currently configured to allow read access from any user on the Internet.” The message included a list of six of Respondent’s Buckets that were “configured to allow read access from anyone on the Internet,” including the Health and Genetic Buckets. The message encouraged Respondent to promptly review its Buckets and provided a link to the AWS Management Console where Respondent could have quickly reviewed its Bucket access controls and a link to guidance about
how to restrict Bucket access. Despite this warning, Respondent did not restrict access to the Health and Genetic Buckets.

31. Respondent received its second warning in November 2018, when a security testing company that conducted a web application penetration test for Respondent “found that uploaded DNA data was being stored in Amazon S3 . . . without any access controls.” Despite this warning, Respondent did not restrict access to the Health and Genetic Buckets.

32. In June 2019, Respondent received its third warning. On June 27, 2019, a security researcher emailed Respondent’s support inbox regarding a security issue with Respondent’s web application. On July 1, 2019, the security researcher sent Respondent an email with publicly accessible links to Health Reports and files in the Health and Genetic Buckets. The security researcher stated that he had “been able to confirm via the details” that the publicly exposed files pertained to “real individuals and real doctors” and that they were not “testing or ‘made up’ records.” The security researcher later reported his findings to the news media, which published articles about this breach of security in July 2019.

33. In July 2019, Respondent began an investigation into the public exposure of the Health and Genetic Buckets. Because Respondent had not taken steps to log access to the Health and Genetic Buckets, Respondent was unable to determine exactly when the Buckets had been created or whether anyone other than the security researcher had accessed, downloaded, or transferred any of the sensitive health, genetic, and personal information they contained.

34. In August 2019, Respondent notified affected consumers about the breach. Numerous consumers complained to Respondent about its failure to safeguard their sensitive information. For example, one consumer wrote to Respondent: “I am horrified that my dna is out there for anyone to use.” Another wrote: “This is worse than credit card and financial info because it’s related to my health.” A third simply said: “Shame on Vitagene for not having its consumers in their best interest.”

35. Because Respondent did not maintain a data inventory, from approximately 2016 through July 1, 2019, Respondent could not search the Health and Genetic Buckets in response to consumers’ requests for Respondent to delete their data.

**Count I**

**Security Misrepresentation – Exceeding Industry Standards**

36. As described in Paragraph 12, Respondent represented, directly or indirectly, expressly or by implication, that it exceeded industry-standard security practices to protect the privacy of consumers’ sensitive personal information, including their health and genetic information.

37. In fact, as set forth in Paragraphs 26-35, Respondent’s security practices did not exceed industry-standard security practices to protect the privacy of consumers’ sensitive personal information. Therefore, the representations set forth in Paragraph 12 are false or misleading.
Count II
Security Misrepresentation – Storing DNA Results without Identifying Information

38. As described in Paragraphs 15-16, Respondent represented, directly or indirectly, expressly or by implication, that it stored consumers’ DNA results without name or any other common identifying information.

39. In fact, as set forth in Paragraphs 9 and 28, Respondent stored DNA results with name and other common identifying information. Therefore, the representations set forth in Paragraphs 15-16 are false or misleading.

Count III
Privacy Misrepresentation – Data Deletion

40. As described in Paragraph 17, Respondent represented, directly or indirectly, expressly or by implication, that if a consumer requested deletion of his or her data, Respondent would remove all of that consumer’s information.

41. In fact, as set forth in Paragraph 35, because Respondent did not have an inventory of consumers’ information, including in the Health and Genetic Buckets it exposed publicly, in at least some instances, Respondent could not delete all consumer information for consumers who requested deletion of their data. Therefore, the representations set forth in Paragraph 17 are false or misleading.

Count IV
Privacy Misrepresentation – Saliva Sample Destruction

42. As described in Paragraph 18, Respondent represented, directly or indirectly, expressly or by implication, that it destroys the consumer’s physical DNA saliva sample shortly after the sample has been analyzed.

43. In fact, as set forth in Paragraph 19, beginning in approximately December 2016, Respondent did not have measures in place to ensure that consumers’ saliva samples were destroyed shortly after they had been analyzed. In particular, Respondent did not have a contract provision with its genotyping laboratory partner requiring such destruction. Therefore, the representations set forth in Paragraph 18 are false or misleading.

Count V
Unfair Adoption of Material Retroactive Privacy Policy Changes Regarding Sharing of Consumers’ Sensitive Personal Information with Third Parties

44. As described in Paragraphs 20-25, in April and December 2020, Respondent posted revised privacy policies containing material changes to Respondent’s practices for sharing consumers’ sensitive personal information with third parties, including the health and genetic information of consumers who purchased products and services from Respondent solely before April 2020. Respondent made those material retroactive changes without taking any additional steps to notify consumers or obtain consumers’ consent even though Respondent’s numerous
prominent privacy and security claims when it had collected consumers’ sensitive personal information, as described in Paragraphs 10-16, demonstrate Respondent’s understanding that consumers consider it important to be able to control and limit access to such information. Unauthorized access to a consumer’s sensitive health and genetic information can lead to a variety of harms, including discrimination or economic or reputational injury. Accordingly, Respondent’s retroactive application of its revised privacy policies caused or is likely to cause substantial injury to consumers that is not outweighed by countervailing benefits to consumers or competition and is not reasonably avoidable by consumers. This is an unfair act or practice.

**VIOLATIONS OF SECTION 5 OF THE FTC ACT**

45. The acts and practices of Respondent as alleged in this complaint constitute unfair or deceptive acts or practices, in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act.

THEREFORE, the Federal Trade Commission this ______ day of ______, 2023, has issued this Complaint against Respondent.

By the Commission.

April J. Tabor
Secretary

SEAL: